GlobeImmune to Present at the Aegis Capital Corp. 2014 Healthcare Conference
03 sept. 2014 07h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - September 03, 2014) - GlobeImmune, Inc.
(NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the Aegis Capital Corp....
GlobeImmune Announces Second Quarter 2014 Financial Results
15 août 2014 16h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 15, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced its second quarter 2014 corporate highlights and financial results. The net loss for the second...
GlobeImmune Files Registration Statement for Proposed Initial Public Offering
02 juil. 2012 17h58 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - Jul 2, 2012) - GlobeImmune, Inc., today announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating...
GlobeImmune's GI-4000 in Combination With Gemcitabine Following Surgery Shows Evidence of an Improvement in Survival in a Phase 2b Clinical Trial With Ras Mutation Positive Pancreas Cancer
27 juin 2012 09h15 HE
|
GlobeImmune, Inc.
BARCELONA, SPAIN--(Marketwire - Jun 27, 2012) - GlobeImmune, Inc., today announced that GI-4000 in combination with gemcitabine showed evidence of an improvement in overall survival for...
Survival Data From GlobeImmune's Phase 2b Study in Patients With Resected Pancreas Cancer to Be Presented at ESMO 14th World Congress on Gastrointestinal Cancer
31 mai 2012 19h58 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - May 31, 2012) - GlobeImmune, Inc., today announced that initial survival data from GI-4000-02, a Phase 2b study of the company's lead cancer product candidate,...
GlobeImmune Initiates Phase 1 Clinical Trial of GI-6301 in Brachyury Expressing Cancers
08 févr. 2012 07h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - Feb 8, 2012) - GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to be conducted at the National Cancer Institute (NCI) to investigate the...
GlobeImmune Promotes Jeffrey Dekker to Vice President of Finance
31 août 2011 07h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - Aug 31, 2011) - GlobeImmune Inc. announced today the promotion of Jeffrey Dekker to Vice President of Finance. Mr. Dekker previously served as Controller and Senior...
GlobeImmune Reports Positive Results for Two Therapeutic Vaccines, GI-4000 and GI-6207
01 juin 2011 07h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - Jun 1, 2011) - GlobeImmune Inc. today presented safety and immunogenicity data from two clinical studies of therapeutic vaccines based on the Company's Tarmogen®...
GlobeImmune Receives Three Grants Under Federal Therapeutic Discovery Project Program
03 nov. 2010 08h00 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 3, 2010) - GlobeImmune Inc. today announced that the company has been awarded three grants totaling $733,438 under the federal Therapeutic Discovery...
UPDATE: Phase 2b Study Demonstrates GlobeImmune's GI-5005 HCV Therapeutic Vaccine Increases Sustained Virologic Response by 12 Percent in Patients Who Previously Failed Therapy With Standard of Care
30 oct. 2010 11h55 HE
|
GlobeImmune Inc.
LOUISVILLE, CO--(Marketwire - October 30, 2010) - GlobeImmune Inc. today announced additional data from the GI-5005-02 Phase 2b study demonstrating that GI-5005, the Company's investigational...